Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases

Overview

Journal Allergy Asthma Immunol Res

Date 2020 Nov 16

PMID 33191675

Citations 6

Authors

Phornsiri Pechsrichuang

Supannika Namwongnao

Alain Jacquet

Affiliations

Soon will be listed here.

Abstract

Recent findings on the mechanism of allergen-specific immunotherapy (AIT) have revisited the role of immunoglobulin G (IgG) as the development of specific blocking IgG antibodies appeared critical for the successful suppression of T-helper 2 (Th2)-biased allergic responses. Consequently, any form of molecular AIT-promoting potent allergen-specific neutralizing antibodies would be preferred to conventional administration of allergen extracts. The potent immunogenicity of virus-like particles (VLPs) could be harnessed for that purpose. The particle size (20-200 nm) optimizes uptake by antigen-presenting cells as well as lymphatic trafficking. Moreover, the display of antigens in repetitive arrays promotes potent B cell activation for the development of sustained antibody responses. The presentation of self-antigens on the particle surface was even capable to break B cell tolerance. In this review, we describe the immunomodulatory properties of the 3 VLP-based strategies designed so far for the treatment of allergic disease: VLP packaged with CpG motifs as well as chimeric particles displaying pro-Th2/Th2 cytokines or allergens (full-length or B cell epitopes).

Citing Articles

Virus-like particle encapsulation of functional proteins: advances and applications.

Sun X, Lian Y, Tian T, Cui Z Theranostics. 2024; 14(19):7604-7622.

PMID: 39659581 PMC: 11626933. DOI: 10.7150/thno.103127.

Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.

Berreiros-Hortala H, Vilchez-Pinto G, Diaz-Perales A, Garrido-Arandia M, Tome-Amat J Int J Mol Sci. 2024; 25(13).

PMID: 39000536 PMC: 11242184. DOI: 10.3390/ijms25137429.

Cell and biomaterial delivery strategies to induce immune tolerance.

Scotland B, Shaw J, Dharmaraj S, Caprio N, Cottingham A, Lasola J Adv Drug Deliv Rev. 2023; 203:115141.

PMID: 37980950 PMC: 10842132. DOI: 10.1016/j.addr.2023.115141.

Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines.

Pazos-Castro D, Margain C, Gonzalez-Klein Z, Amores-Borge M, Yuste-Calvo C, Garrido-Arandia M Front Immunol. 2022; 13:986823.

PMID: 36159839 PMC: 9492988. DOI: 10.3389/fimmu.2022.986823.

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review.

Lee S, Shin Y, Kang S, Kim T, Lee S Immune Netw. 2022; 22(1):e12.

PMID: 35291653 PMC: 8901700. DOI: 10.4110/in.2022.22.e12.

References

Hong S, Zhang Z, Liu H, Tian M, Zhu X, Zhang Z . B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4 T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen. Immunity. 2018; 49(4):695-708.e4. DOI: 10.1016/j.immuni.2018.08.012. View

Hammad H, Lambrecht B . Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity. 2015; 43(1):29-40. DOI: 10.1016/j.immuni.2015.07.007. View

Chackerian B, Lenz P, Lowy D, Schiller J . Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol. 2002; 169(11):6120-6. DOI: 10.4049/jimmunol.169.11.6120. View

Ward A, Wilson I . Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci. 2015; 40(2):101-7. PMC: 4310573. DOI: 10.1016/j.tibs.2014.12.006. View

Rohn T, Jennings G, Hernandez M, Grest P, Beck M, Zou Y . Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006; 36(11):2857-67. DOI: 10.1002/eji.200636658. View

Guan Q, Ma Y, Aboud L, Weiss C, Qing G, Warrington R . Targeting IL-23 by employing a p40 peptide-based vaccine ameliorates murine allergic skin and airway inflammation. Clin Exp Allergy. 2012; 42(9):1397-405. DOI: 10.1111/j.1365-2222.2012.04022.x. View

Thoms F, Jennings G, Maudrich M, Vogel M, Haas S, Zeltins A . Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. J Allergy Clin Immunol. 2019; 144(1):193-203. DOI: 10.1016/j.jaci.2019.01.050. View

Mohsen M, Gomes A, Vogel M, Bachmann M . Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines (Basel). 2018; 6(3). PMC: 6161069. DOI: 10.3390/vaccines6030037. View

Ma Y, HayGlass K, Becker A, Fan Y, Yang X, Basu S . Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med. 2007; 176(5):439-45. DOI: 10.1164/rccm.200610-1405OC. View

10.

Huber M . Activation/Inhibition of mast cells by supra-optimal antigen concentrations. Cell Commun Signal. 2013; 11(1):7. PMC: 3598417. DOI: 10.1186/1478-811X-11-7. View

11.

Orengo J, Radin A, Kamat V, Badithe A, Ben L, Bennett B . Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018; 9(1):1421. PMC: 5897525. DOI: 10.1038/s41467-018-03636-8. View

12.

Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann M . Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2003; 32(11):3305-14. DOI: 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J. View

13.

Chackerian B, Lowy D, Schiller J . Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A. 1999; 96(5):2373-8. PMC: 26791. DOI: 10.1073/pnas.96.5.2373. View

14.

Escolano A, Gristick H, Abernathy M, Merkenschlager J, Gautam R, Oliveira T . Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019; 570(7762):468-473. PMC: 6657810. DOI: 10.1038/s41586-019-1250-z. View

15.

Shamji M, Durham S . Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017; 140(6):1485-1498. DOI: 10.1016/j.jaci.2017.10.010. View

16.

Brune K, Leneghan D, Brian I, Ishizuka A, Bachmann M, Draper S . Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep. 2016; 6:19234. PMC: 4725971. DOI: 10.1038/srep19234. View

17.

Krieg A . Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5(6):471-84. DOI: 10.1038/nrd2059. View

18.

Bachmann M, Zinkernagel R . Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997; 15:235-70. DOI: 10.1146/annurev.immunol.15.1.235. View

19.

Stebegg M, Kumar S, Silva-Cayetano A, Fonseca V, Linterman M, Graca L . Regulation of the Germinal Center Response. Front Immunol. 2018; 9:2469. PMC: 6209676. DOI: 10.3389/fimmu.2018.02469. View

20.

Leb V, Jahn-Schmid B, Kueng H, Schmetterer K, Haiderer D, Neunkirchner A . Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. J Allergy Clin Immunol. 2009; 124(1):121-8. DOI: 10.1016/j.jaci.2009.04.008. View